Immune checkpoint inhibitors such as PD-1/PD-L1 and CTLA4 blockade are emerging cancer immunotherapies which block the immunosuppressive mechanisms which help tumor evade immune surveillance. This evidence concerns the gene CD274 and neoplasm.